US 11040036
Pyruvate kinase activators for use in treating blood disorders
granted A61KA61K31/5025A61K31/506
Quick answer
US patent 11040036 (Pyruvate kinase activators for use in treating blood disorders) held by Agios Pharmaceuticals, Inc. expires Mon Jun 17 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Agios Pharmaceuticals, Inc.
- Grant date
- Tue Jun 22 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Jun 17 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 26
- CPC classes
- A61K, A61K31/5025, A61K31/506, A61K31/519, A61K45/06